Optimal duration of anticoagulation therapy for venous thromboembolism in autoimmune diseases

Published:November 09, 2021DOI:https://doi.org/10.1016/j.ejim.2021.11.001
      Venous thromboembolism (VTE) is a common issue in patients with autoimmune diseases. One of the clinically relevant issues for VTE in autoimmune disorders is the optimal duration of anticoagulation therapy for the prevention of recurrent VTE. Currently, autoimmune disorders are thought to be a relatively strong risk factor for recurrent VTE, which leads to the recommendation of extended anticoagulation therapy of indefinite duration in the current VTE guidelines [
      • Konstantinides S.V.
      • Meyer G.
      The 2019 ESC guidelines on the diagnosis and management of acute pulmonary embolism.
      ]. However, these considerations have been based on observational studies. The Letter to the Editor by Ruiz-Sada et al. [
      • Ruiz-Sada P.
      • Palacios-García L.
      • Sada-Sainz J
      Venous thromboembolism treatment duration in autoimmune diseases. research trends.
      ] comprehensively summarizes the recent evidences regarding VTE and autoimmune disorders including our recent report [
      • Yamashita Y.
      • Morimoto T.
      • Kadota K.
      • Ono K.
      • Kimura T.
      Autoimmune disorders and venous thromboembolism: an update from the COMMAND VTE registry.
      ], and suggests deep insights and interesting future perspectives for this issue.
      To read this article in full you will need to make a payment

      References

        • Konstantinides S.V.
        • Meyer G.
        The 2019 ESC guidelines on the diagnosis and management of acute pulmonary embolism.
        Eur Heart J. 2019; 40: 3453-3455
        • Ruiz-Sada P.
        • Palacios-García L.
        • Sada-Sainz J
        Venous thromboembolism treatment duration in autoimmune diseases. research trends.
        Eur J Intern Med. 2021; https://doi.org/10.1016/j.ejim.2021.10.020
        • Yamashita Y.
        • Morimoto T.
        • Kadota K.
        • Ono K.
        • Kimura T.
        Autoimmune disorders and venous thromboembolism: an update from the COMMAND VTE registry.
        Eur J Intern Med. 2021; 84: 106-108
        • Borjas Howard J.
        • Ruiz-Sada P.
        • de Leeuw K.
        • L´opez-Jim˜nenez L.
        • Font C.
        • Marchena P.J.
        • et al.
        Risk of recurrent venous thromboembolism in patients with autoimmune diseases: data from the Registro Informatizado de Enfermedad TromboEmb´olica (RIETE) registry.
        Br J Haematol. 2021; 194: 195-199